Incidental Prostate Cancer in Patients Treated for Benign Prostate Hyperplasia in the Period of 21 Years

• Published in: Acta clinica Croatica (Tisak) Vol. 57; no. Suppl 1; pp. 71 - 76
• Main Authors: Pirša, Matea, Pezelj, Ivan, Knežević, Matej, Spajić, Borislav, Tomašković, Igor, Reljić, Ante, Ružić, Boris
• Format: Journal Article
• Language: English
• Published: Croatia Sestre Milosrdnice University hospital, Institute of Clinical Medical Research 01.10.2018
• Subjects: Aged; Benign prostate hyperplasia; BPH; Humans; Hyperplasia; Incidental prostate cancer; Male; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Hyperplasia - complications; Prostatic Neoplasms - complications; Retrospective Studies; TURP; TURP; Incidental prostate cancer; BPH; Benign prostate hyperplasia
• DOI: 10.20471/acc.2018.57.s1.11
• ISSN: 0353-9466

The aim of this study was to determine the incidence of incidental prostate cancer and its clinical significance among patients who underwent transurethral prostate resection or transvesical adenomectomy for benign prostate hyperplasia at the Department of Urology in Sestre milosrdnice University Hospital Center from January 1997 to December 2017. A total of 277/4,372 (6.34%) patients from our cohort were diagnosed with incidental prostate cancer (mean age 74.5 years). Due to incomplete data, 12 patents were excluded from further analysis. 44.91% (119/265 patents) of our cohort were stage T1a and 55.09% (146/265) were stage T1b. Clinically significant prostate cancer was found in 168/265 patients (63.40%). When divided into two groups, Gleason score ≤6 (mean age 73.58 years) and Gleason score ≥7 (mean age 75.77 years), the results showed that Gleason score ≥7 patients were significantly older (p=0.0104) and that the tumor extent among patients in this group (mean = 34.58%) was higher than that in Gleason score ≤6 group (mean = 11.11%) (p=0.0169). More than a half of patients in our cohort had T1b stage prostate cancer. We found that 63.4% of carcinomas were clinically significant, with 52/265 (19,62%) patients affected by ISUP grade 4 and 5 cancers. Based on our research, we cannot give any recommendations regarding incidental prostate cancer treatment due to lacking preoperative (PSA, DRE) and follow-up data.